Ping An CSI HK Equities Medical and Health Integration ETF (159718)
- 0.890
- -0.016-1.77%
Ping An CSI HK Equities Medical and Health Integration ETF (159718) News
Day 3 of the 2026 National Reimbursement Drug List (NRDL) negotiations: Intensive talks on new "-tinib" drugs as star companies such as BeiGene and Kelun Biotech take the stage.
1) Intensive negotiations for new "-tinib" class drugs took place in the morning, with innovative pharmaceutical companies such as InnoCare Pharma, Shouyao Holdings, and Jiangsu Wellshine making successive appearances; 2) In the afternoon session, leading pharmaceutical firms including Kelun Biotech and BeiGene were featured, engaging in a two-pronged strategic dynamic in the ADC sector characterized by "expansion within the catalog" and "new additions outside the catalog."
Day 2 of the 2026 National Reimbursement Drug List (NRDL) negotiations: Two CAR-T therapies vie for basic medical insurance coverage as executives from multiple companies maintain on-site presence.
1. As the national reimbursement drug negotiations entered their second day, several innovative drugs and products with high clinical value were brought to the negotiating table; 2. In line with past practice, innovative drugs that are relatively more difficult to negotiate, such as anti-cancer medications and treatments for rare diseases, tend to be scheduled more intensively in the subsequent days. The lineup of participating companies suggests that this arrangement has largely been maintained.
On-the-ground report from Day 2 of the 2026 NRDL negotiations: Blockbuster oncology drugs, including CAR-T therapies and the world’s first bispecific antibody-drug conjugate (ADC), made their debut, while products covered by commercial insurance sought to
① On the second day of national reimbursement negotiations, the focus shifted to innovative oncology drugs, with nearly 20 companies—including Hengrui Medicine, Eli Lilly and Co, Novartis, and Innovent Biologics—participating in the morning session; ② In the afternoon, multinational pharmaceutical firms took center stage, with Merck & Co, Roche, and Johnson & Johnson successively entering negotiations as several blockbuster innovative drugs were brought to the table; ③ Companies such as Heyuan Biopharma and JW Therapeutics, which emerged as new entrants in commercial health insurance formularies last year, are once again attempting to break into the basic medical insurance scheme, marking the transition of dual-formulary alignment into the practical implementation phase.
Day One of the 2026 National Reimbursement Drug List Negotiations: Representatives from Multiple Companies Display Visible Joy as Traditional Chinese Medicine and Chronic Disease Drugs Take Center Stage
The annual national medical insurance catalog negotiations have once again entered the stage of on-site bargaining.
Key Pre-Market News for A-Shares (2026-08-28)
Mini Program: Key Pre-Market News for A-Shares Important News 1. Ministry of Finance: Continue to deepen zero-based budgeting reform, strengthen local government debt management, and optimize the allocation of fiscal resources. On August 26, the Ministry of Finance held a seminar on scientific fiscal management in Hefei, Anhui Province, to study and deploy measures for advancing scientific fiscal management. Lan Foan, Secretary of the Leading Party Members Group and Minister of the Ministry of Finance, attended and delivered remarks. The meeting emphasized the following: First, place greater emphasis on improving efficiency by continuing to deepen zero-based budgeting reform, strengthening performance orientation, enhancing local government debt management, and optimizing the allocation of fiscal resources; Second, place greater emphasis on strengthening coordination, including coordination of budgets and existing resources,
Shares surged more than 16% following the earnings release; what is driving Hansoh Pharmaceutical's growth?
Revenue growth from innovative drugs is not dependent on a proportional increase in selling expenses, while the advancement of overseas clinical trials enhances the likelihood of achieving milestones and realizing sales royalties from collaborative projects.
BeiGene's H1 net profit surges 386% year-on-year, driven by Brukinsa as revenue surpasses $3.2 billion | Financial Report Insights
BeiGene’s performance in the first half of 2026 significantly surpassed the same period last year, with a marked improvement in profitability, validating the effectiveness of its commercialization strategy. According to the company’s announcement, for the six months ended June 30, 2026, BeiGene’s total revenue increased by 32.3% year-on-year to USD 3.219 billion, while net profit surged by 385.8% year-on-year to USD 464 million, accelerating the release of operating leverage effects. Diluted earnings per ADS rose substantially from USD 0.85 in the same period last year to USD 4.01. The core driver was strong demand for its flagship product, Brukinsa (zanubrutinib), in the U.S. and European markets. During the same period, the company’s non-
Since the second half of the year, 47 companies listed on the STAR Market have been surveyed by foreign institutional investors, with five industry leaders drawing particular attention | Review
① In terms of the aggregate volume over the past two months, Beigene, Montage Technology, Espressif Systems, ACM Research Shanghai, and Segway-Ninebot were the STAR Market companies that attracted the most attention from foreign institutional investors; ② A deeper examination of the due diligence conducted by these foreign institutions reveals a key question: within the context of the global AI cycle and supply chain restructuring, can these companies translate their "technology narrative" into tangible orders, gross margins, and cash flow?
Following the commercial launch of mRNA cancer vaccines, which innovative drug sectors are poised for a "GPT moment"?
1. mRNA technology has made its first breakthrough from preventive vaccines into the field of oncology treatment, with brokerage firms hailing it as the "GPT moment" for cancer vaccines; 2. The 2026 WCLC and ESMO annual congresses will be held in Seoul, South Korea, and Madrid, Spain, respectively; 3. It is reported that three ADCs will be featured in late-breaking abstract oral presentations at the WCLC congress, while second-generation immuno-oncology (IO) therapies are also expected to gain significant visibility.
Moderna achieves first success with its "personalized mRNA vaccine," while China's innovative drugs are also in the pipeline.
Moderna’s Phase III clinical trial has, for the first time in a large-scale study, validated the oncological therapeutic value of its personalized mRNA cancer vaccine, with Citi highlighting Chinese companies positioned to benefit. Hengrui’s subsidiary Ruihongdi has advanced its candidate RGL-270 into Phase II trials, reporting promising data for pancreatic cancer; CSPC’s SYS6026 is progressing steadily with a controlled design; while Akeso, Yunding, and CanSino each hold differentiated competitive advantages. The race among Chinese firms to develop mRNA cancer vaccines has officially begun.
Cailian Press Venture Capital Channel: Total financing in the primary market reached approximately RMB 10.6 billion this week, a 25% increase from the previous week; Qianheyibang completed its Series B funding round of over RMB 2 billion.
1. This week (August 8–14), there were 134 investment and financing events in China, a week-on-week decrease of 10.67%; the total disclosed financing amount was approximately RMB 10.59 billion, a week-on-week increase of 25.19%. 2. Sectors such as advanced manufacturing and artificial intelligence were relatively active, with advanced manufacturing recording the highest total disclosed financing of approximately RMB 2.65 billion. 3. Qianheyibang completed its Series B financing round of over RMB 2 billion, marking the largest single investment deal disclosed this week.
Shanghai Industrial Capital’s RMB 1.5 Billion Phase II Fund Successfully Closed! Exclusive Interview with Liu Dawei on Decoding Investment "Blind Boxes"
① With the recent completion of the first closing of the Shanghai Biopharmaceutical Fund Phase II, raising RMB 1.5 billion, Shanghai Industrial Capital has effectively established a closed-loop investment framework covering the entire lifecycle of the biopharmaceutical sector. ② Each fund employs distinct strategies. As Liu Dawei stated, “Appetizers, hot soups, and desserts are prepared separately, with each dish requiring precise control of heat.” ③ Liu Dawei also provided insights into the future outlook and trends of the vaccine industry.
CRO Outperforms CPO in August: Is a Rally in Pharmaceutical Stocks Next After the Optical Module Surge?
① The semi-annual report indicates that the operating performance and order backlog of multiple CRO companies have resumed rapid growth, driven by a robust recovery in client demand; ② In Q2, fund allocations to the pharmaceutical sector overall dropped to historic lows, yet innovative drugs and CROs emerged as the primary areas for contrarian accumulation by capital at market bottoms; ③ The CDMO sub-sector has entered a critical period for new contract signings and the volume ramp-up of major overseas products.
Spring for Non-Tech Sectors? Pharmaceutical Sector Surpasses Semiconductors in Research Interest
① Last week, the pharmaceutical and biotechnology sector received 104 visits from public mutual fund institutions for research purposes, ranking first among all SW1 sectors, with nearly double the number of visits compared to the second-ranked sector. ② The sector’s valuation remains at a relatively low level and offers ample growth potential, making it attractive for portfolio allocation and prompting multiple public mutual fund institutions to actively conduct research. ③ The sector may face risks of volatility and divergence, and investors should avoid blind investment.
Innovative pharmaceuticals and the CDMO sector attract intensive institutional research visits, with ESMO-disclosed data and overseas business development progress drawing attention.
① During this week (August 3 to August 9), a total of 57 A-share companies received institutional investor visits. ② Among them, BeiGene received the highest number of visits, hosting 207 institutions. ③ Zelgen Biopharmaceuticals and Zhejiang Jiuzhou Pharmaceutical ranked among the top ten listed companies by number of visiting institutions, with 97 and 77 institutions respectively.
Express News | Most Hong Kong-listed innovative drug stocks rose, with Zai Lab surging over 14%, Wuxi Bio gaining more than 6%, Wuxi Apptec rising nearly 6%, and Ascletis Pharma and Confo Therapeutics each climbing over 4%.
First-half net profit surges by several-fold, overseas licensing deals hit record highs, and more than RMB 4 billion in losses reversed—multiple innovative drugmakers report explosive earnings growth.
① BeiGene has anchored its full-year operating profit at the billion-dollar level; RemeGen achieved a significant turnaround through a major BD licensing deal with AbbVie; Innovent’s GLP-1 and other new pipelines are stepping in to drive growth. ③ Industry narratives are shifting from ‘pipeline storytelling’ to performance realization, with policy support and a surge in outbound BD deals accelerating the validation of commercialization closed loops.
BeiGene reported a 30% year-over-year revenue increase and a 151% surge in net profit for Q2, raising its full-year revenue guidance to $6.6–6.8 billion.
More updates to follow.
Nine consecutive limit-up "speculative stock": trading halt review completed; resumes trading tomorrow! | Selected Post-Market Announcements
The nine-limit-up "speculative stock" will resume trading starting tomorrow! The "innovative drug leader" reported a 151% year-over-year surge in net profit for Q2; a major photovoltaic company will be removed from the special treatment list and halt trading for one day...
Results of the 12th batch of national centralized procurement announced, with leading manufacturers securing major orders.
① All 65 products were successfully procured, with 327 companies and 521 products provisionally selected; ② Competitive dynamics for several high-profile products have been reshaped, with leading enterprises securing a larger share of provisional selections, and procurement rules further optimized; ③ The 'anti-grind' (anti-excessive competition) mechanism is showing initial effectiveness, as centralized procurement shifts from price-driven competition toward comprehensive capability assessment.